What if you'd held AKBA?
A $1,000 investment in Akebia Therapeutics, Inc. (AKBA) at the month-end close of 2014-03 would be worth $45.25 at the close of 2026-08 — -95.5% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $4,117.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2014
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2014 | $1,000 | — |
| 2015 | $1,110 | +11.0% |
| 2016 | $894 | -19.4% |
| 2017 | $1,277 | +42.8% |
| 2018 | $475 | -62.8% |
| 2019 | $543 | +14.3% |
| 2020 | $241 | -55.7% |
| 2021 | $194 | -19.3% |
| 2022 | $49.57 | -74.5% |
| 2023 | $107 | +114.9% |
| 2024 | $163 | +53.2% |
| 2025 | $138 | -15.3% |
| 2026 | $76.03 | -45.0% |
Best and worst month-end to buy
The best single month-end close to have bought AKBA was 2022-10 ($0.26): $1,000 then is $3,471 today. The worst was 2014-06 ($27.79): $1,000 then is $31.85.
FAQ
What would $1,000 in AKBA be worth today?
A $1,000 investment in Akebia Therapeutics, Inc. (AKBA) at the start of 2014 would be worth about $45.25 today, a total return of -95.5%. Dividends are reinvested in these figures.
What were the best and worst years for AKBA?
Akebia Therapeutics, Inc. (AKBA)'s strongest calendar year since 2014 was 2023, a +114.9% return — $1,000 held through that year became about $2,149 by year-end. Its weakest year was 2022, at -74.5%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in AKBA have grown?
Investing $100 at the end of every month since 2014-03 would have grown to about $6,650 on $15,000 invested.
Did AKBA beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $4,117. AKBA trailed the S&P 500 by +98.9% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Akebia Therapeutics, Inc. (AKBA) historical total-return data from 2014-03 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.